Sobi received an FDA complete response letter for its gout combination treatment, citing concerns tied to third-party manufacturing sites. The agency’s action centers on production problems, requiring additional work before the combination can move forward. The CRL indicates Sobi will need to address issues at the external manufacturing level rather than advancing only clinical revisions. While the company is not described in detail here regarding timelines, the regulator’s request for additional information suggests a pause tied to quality and supply assurance. For the industry, CRLs that reference third-party sites highlight how manufacturing governance and vendor qualification can be decisive in late-stage regulatory outcomes—even when clinical programs are otherwise ready. This development also functions as a reminder to biotech operators that integration of manufacturing risk management into overall development timelines remains a critical lever.